Focus on HIV Care

Back to articles

Red card: Pharmacogenetic screening targets abacavir hypersensitivity

KEY POINT

Data presented at the International AIDS Society (IAS) conference in July 2007 suggest that screening patients for the HLA-B*5701 allele can reduce the incidence of hypersensitivity reactions to abacavir (Ziagen— GlaxoSmithKline) therapy. Patients who have tested positive for this allele may present to physicians and pharmacists a red card the manufacturer has developed that describes their need for alternative antiretroviral agents.